Hyperlipidemia: Clinical Trials

68 trials for Hyperlipidemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

68 completed. 68 Phase 3, 10 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 368Completed 68
Phase 210Completed 10

Follow Hyperlipidemia: new trials by email Literature Review of Hyperlipidemia trials Research Report on Hyperlipidemia

Trials (filtered) newest first · largest first

All 68 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia
AK102, Placebo - Hyperlipidemia
Phase 3CompletedAkeso2462022-01-262025-03-06
A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia
AK102, Placebo - Hyperlipidemia
Phase 3CompletedAkeso1222021-11-042025-02-28
A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia
AK102, Placebo - Hyperlipidemia
Phase 3CompletedAkeso4642021-11-032025-03-06
A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C
K-877 0.1 mg tablet, Fenofibrate 200 mg capsule, Placebo tablet - Hyperlipidemia
Phase 3CompletedKowa Company, Ltd.3532021-09-172025-05-23
Effect of Evolocumab on Coronary Atherosclerosis
Evolocumab, 18F-NaF PET, CCTA - Cardiovascular Disease, Hyperlipidemia
Phase 3CompletedCedars-Sinai Medical Center552019-03-192024-07-17
Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia
Temisartan+Amlodipine+Rosuvastatin (Combination drug), Temisartan+Amlodipine, Temisartan+Rosuvastatin - Hypertension, Hyperlipidemia
Phase 3CompletedYuhan Corporation2022017-04-112019-01-16
The Effect of Intranasal Insulin on Hepatic and Intestinal Triglyceride-rich Lipoprotein Production
Insulin, Placebo - Hyperlipidemia
Phase 2 / Phase 3CompletedUniversity Health Network, Toronto92016-04-142017-05-08
Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia
Bococizumab 150mg, Bococizumab 75mg, Bococizumab 150mg placebo - Hyperlipidemia
Phase 3CompletedPfizer2992015-06-012017-12-19
Clinical Trial to Evaluate the Efficacy and Safety of CKD-391
Atorvastatin10mg, Ezetimibe10mg, Atorvastatin10mg, Ezetimibe placebo, Atorvastatin20mg, Ezetimibe10mg - Hyperlipidemia
Phase 3CompletedChong Kun Dang Pharmaceutical3852015-03-012016-01-28
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Bococizumab (PF-04950615; RN316), Placebo - Hyperlipidemia
Phase 3CompletedPfizer7462014-10-282018-07-31
Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia
HGP0904, HGP0608, HGP0816 - Hypertension, Hyperlipidemia
Phase 3CompletedHanmi Pharmaceutical Company Limited1462014-07-012016-10-20
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins
Bococizumab (PF-04950615;RN316), Atorvastatin, Placebo for Bococizumab (PF-04950615;RN316) - Hyperlipidemia
Phase 3CompletedPfizer1842014-06-012017-12-14
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
Atorvastatin, Placebo to Atorvastatin, Placebo to Ezetimibe - Hyperlipidemia
Phase 3CompletedAmgen5112013-12-102018-11-29
Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia
YH16410, Rosuvastatin, Telmisartan - Hyperlipidemia, Hypertension
Phase 3CompletedYuhan Corporation2102013-11-012014-07-08
Study to Evaluate Efficacy and Safety of PreLipid® on Subjects With Higher Than Normal Blood Lipid Levels
Study Dietary Supplement (Prelipid 500 mg capsules), Placebo - Hyperlipidemia
Phase 3CompletedPreEmptive Meds, Pvt. Ltd1802013-11-012015-05-15
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
Bococizumab (PF-04950615; RN316), Placebo - Hyperlipidemia
Phase 3CompletedPfizer21392013-10-292018-07-31
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Bococizumab (PF-04950615;RN316), Placebo - Hyperlipidemia
Phase 3CompletedPfizer7112013-10-012017-05-17
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
Evolocumab, Placebo - Hyperlipidemia
Phase 3CompletedAmgen3312013-02-072019-06-17
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
Evolocumab, Placebo to Evolocumab, Ezetimibe - Hyperlipidemia
Phase 3CompletedAmgen3072013-01-242020-07-20
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
Evolocumab, Ezetimibe, Placebo to Evolocumab - Hyperlipidemia
Phase 3CompletedAmgen6152013-01-212022-11-08

Showing 20 of 68. Sign in to see all of them.

Narrower conditions

Hyperlipidemias (68)  ·  Hypertension (12)  ·  Hypercholesterolemia (11)  ·  Diabetes Mellitus (5)  ·  Hyperlipoproteinemia Type II (5)  ·  Diabetes Mellitus, Type 2 (4)  ·  Hypertriglyceridemia (4)  ·  Insulin Resistance (4)  ·  Obesity (4)  ·  HIV Infections (3)  ·  Dyslipidemias (2)  ·  Heart Diseases (2)  ·  Cardiovascular Diseases (1)  ·  Coronary Artery Disease (1)  ·  Coronary Disease (1)

Broader conditions

Lipid Metabolism Disorders (68)  ·  Metabolic Diseases (68)  ·  Nutritional and Metabolic Diseases (68)  ·  Dyslipidemias (66)  ·  Cardiovascular Diseases (14)  ·  Vascular Diseases (14)  ·  Glucose Metabolism Disorders (11)  ·  Endocrine System Diseases (9)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5)  ·  Genetic Diseases, Inborn (5)  ·  Hyperinsulinism (5)  ·  Hyperlipoproteinemias (5)  ·  Lipid Metabolism, Inborn Errors (5)  ·  Metabolism, Inborn Errors (5)  ·  Body Weight (4)

Interventions

Atorvastatin (16)  ·  torcetrapib (7)  ·  Ezetimibe (6)  ·  Fenofibrate (6)  ·  Simvastatin (6)  ·  evolocumab (6)  ·  bococizumab (5)  ·  Rosuvastatin Calcium (3)  ·  Atazanavir Sulfate (2)  ·  Ezetimibe, Simvastatin Drug Combination (2)  ·  MK-0524 (2)  ·  Niacin (2)  ·  Sitagliptin Phosphate (2)  ·  Tea (2)  ·  (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid (1)

Sponsors

Pfizer (12)  ·  Amgen (5)  ·  Merck Sharp & Dohme LLC (4)  ·  Akeso (3)  ·  Hanmi Pharmaceutical Company Limited (3)  ·  Solvay Pharmaceuticals (3)  ·  Abbott (2)  ·  Chonbuk National University Hospital (2)  ·  Organon and Co (2)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (2)  ·  University Health Network, Toronto (2)  ·  Yuhan Corporation (2)  ·  Cedars-Sinai Medical Center (1)  ·  Chestnut Hill Health System (1)  ·  Chong Kun Dang Pharmaceutical (1)

Countries

United States (29)  ·  Canada (17)  ·  South Korea (16)  ·  France (10)  ·  South Africa (9)  ·  Australia (8)  ·  Germany (8)  ·  Netherlands (8)  ·  Czechia (7)  ·  United Kingdom (7)  ·  Denmark (6)  ·  Spain (6)  ·  Taiwan (6)  ·  Belgium (5)  ·  China (5)

Top investigators

Abbas Delazar, PhD (1)  ·  Ali Eskandari, MD (1)  ·  Andrew R Zolopa (1)  ·  Angel Brea, MD (1)  ·  Barbara C Tilley, PhD (1)  ·  Benjamin G Druss, MD MPH (1)  ·  Byeong Hee Oh, M.D (1)  ·  Chang-Gyu Park, Medicine (1)  ·  Chang-Hsun Hsieh, M.D. (1)  ·  Chih-Tsueng He, M.D. (1)  ·  Chih-ching Wang, M.D. (1)

Results publications

PMID 28304227, PMID 37994400, PMID 29685591, PMID 35277540, PMID 37658997, PMID 17387129, PMID 17387131, PMID 17407645, PMID 19029466, PMID 19029469, PMID 19328244, PMID 19576324, PMID 19952712, PMID 20019677, PMID 20228610, PMID 20435205, PMID 20645885, PMID 21291812, PMID 21613319, PMID 23431291, PMID 23816039, PMID 24584549, PMID 24614112, PMID 24961447, PMID 25057276, PMID 25084280, PMID 27039291, PMID 27742464, PMID 28751575, PMID 29150250, PMID 29673890, PMID 30400924, PMID 31145045, PMID 31529318, PMID 32937023, PMID 33078867, PMID 34486528, PMID 35471192, PMID 35654771, PMID 39098034, PMID 40178463, PMID 41832848

NIH funding

2005 (1), 2014 (1), R01MH070437 (1), R18DK067495 (1)